A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells

Erik Procko,1,8 Geoffrey Y. Berguig,2,8 Betty W. Shen,3 Yifan Song,1 Shani Frayo,4 Anthony J. Converte,2 Daciana Margineantu,4 Garrett Booth,6 Bruno E. Correia,6 Yuanhua Cheng,2 William R. Schief,6 David M. Hockenbery,4 Oliver W. Press,4 Barry L. Stoddard,3 Patrick S. Stayton,2 and David Baker1,7,8

1Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
2Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
3Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
5Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA
6Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
7Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA
8Co-first author

*Correspondence: dabaker@u.washington.edu
http://dx.doi.org/10.1016/j.cell.2014.04.034

SUMMARY

Because apoptosis of infected cells can limit virus production and spread, some viruses have co-opted prosurvival genes from the host. This includes the Epstein-Barr virus (EBV) gene BHRF1, a homolog of human Bcl-2 proteins that block apoptosis and are associated with cancer. Computational design and experimental optimization were used to generate a novel protein called BINDI that binds BHRF1 with picomolar affinity. BINDI recognizes the hydrophobic cleft of BHRF1 in a manner similar to other Bcl-2 protein interactions but makes many additional contacts to achieve exceptional affinity and specificity. BINDI induces apoptosis in EBV-infected cancer lines, and when delivered with an antibody-targeted intracellular delivery carrier, BINDI suppressed tumor growth and extended survival in a xenograft disease model of EBV-positive human lymphoma. High-specificity-designed proteins that selectively kill target cells may provide an advantage over the toxic compounds used in current generation antibody–drug conjugates.

INTRODUCTION

Following virus infection, cells may undergo apoptosis to prevent further virus spread in the host. This has spurred viruses to evolve counteracting mechanisms to prevent host cell death, and during latent infection, these factors may contribute to the development of cancer. In particular, there are multiple cancers associated with Epstein-Barr virus (EBV), including Burkitt’s lymphoma (BL). Apoptosis and cell survival are regulated by the homeostatic balance of B cell lymphoma-2 (Bcl-2) family proteins (reviewed in Martinou and Youle, 2011), which fall into three classes. The “executioners,” Bak and Bax, initiate apoptosis by increasing mitochondrial outer membrane permeability and facilitating the release of mitochondrial cytochrome c to the cytosol, which activates downstream signaling. Six human prosurvival Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-B, Mcl-1, Bcl-w, and Bfl-1) inhibit this process. Counterbalancing these are numerous proapoptotic BH3-only proteins, including Bim. These factors share an ~26 residue Bcl-2 homology 3 (BH3) motif, an amphipathic a-helical element that binds a hydrophobic groove on the surface of the canonical Bcl-2 fold. Cellular stresses activate proapoptotic BH3-only proteins, which bind and inhibit prosurvival Bcl-2 members and directly interact with Bak and Bax to favor mitochondrial permeabilization. Conversely, prosurvival Bcl-2 proteins dampen apoptotic triggers and enhance chemoresistance by sequestering BH3-only proteins or directly inhibiting Bak and Bax. Increased expression of prosurvival Bcl-2 proteins is a common feature of many cancers.

Epstein-Barr virus encodes a prosurvival Bcl-2 homolog, BHRF1, which prevents lymphocyte apoptosis during initial infection by sequestering proapoptotic BH3-only proteins (especially Bim) and interacting directly with the executioner Bak (Altmann and Hammerschmidt, 2005; Desbien et al., 2009; Henderson et al., 1993; Kvansakul et al., 2010). Even though BHRF1 is under the control of an early lytic cycle promoter, low levels of constitutive expression have been observed in some cases of EBV-positive BL when the virus is latent, and it has been speculated that BHRF1 may be a necessary viral factor for lymphogenesis (Kelly et al., 2009; Leao et al., 2007; Watanabe et al., 2010). However, although EBV is one of the earliest viruses to be associated with human cancer, its molecular mechanism of action remains unclear, in part because EBV-positive BLs can have different expression profiles, suggesting that the molecular...
etiology may not be universal (Kelly et al., 2009; Watanabe et al., 2010).

In recent years, computation-based protein design has made considerable progress, including the design of new hyperstable structures (Koga et al., 2012) and the creation of functional sites within existing proteins as scaffolds (Fleishman et al., 2011; Procko et al., 2013). However, except in a few rare instances (Correia et al., 2014; Lanci et al., 2012), the design of new structures that are also functional is a largely unmet challenge. Here, we describe the creation of a picomolar inhibitor of BHRF1 by designing a new protein de novo for optimum interactions. The designed BHRF1 inhibitor triggers apoptosis in several EBV-positive cancer lines, and when delivered with an antibody-targeted carrier system, the inhibitor suppresses tumor progression and extends survival in an animal model of human EBV-positive lymphoma.

RESULTS

BHRF1-Binding Proteins Created by Grafting Bim-BH3 Side Chains to a Helical Scaffold

Prosurvival Bcl-2 proteins share a similar fold that resembles a cupped hand, with a characteristic hydrophobic surface groove that clasps one side of an amphipathic BH3 motif helix (Kvansakul et al., 2010; Martinou and Youle, 2011). Rigidifying BH3 peptides with hydrocarbon staples, disulfides, or lactam bridges on the noninteracting back side of the helix can reduce the entropic cost of a partially folded peptide acquiring a rigid helical conformation upon binding and improves BH3 peptide affinity (Azzarito et al., 2013). We reasoned that building a folded structure around a BH3 peptide would similarly prestabilize the bound conformation but also provide additional interactions for increased affinity and specificity. In previous work, interacting residues of the BH3 motif were grafted to the surface of a minimal structured peptide, and when delivered with an antibody-targeted carrier system, the inhibitor suppresses tumor progression and extends survival in an animal model of human EBV-positive lymphoma.

Creating New Proteins for Optimized Interactions with the BHRF1 Ligand-Binding Groove

Designed proteins from side-chain grafting are limited by the assumed rigid backbone of the scaffold. To escape this constraint, a second design strategy was used that builds protein structures de novo using proteins of known structure only as topology guides (Correia et al., 2014). The Bim-BH3 helix from the complex with BHRF1 was taken as a folding nucleus, and helical bundle structures were assembled around it using fragments from the PDB, followed by cycles of sequence design and structure minimization. Cα-Cα atom-pair distances from the topology guide constrained the assembling protein to within 3.0 Å root mean square deviation (rmsd) of the guide. Independent runs of this stochastic design protocol gave an ensemble of structural homologs, roughly centered on the guide scaffold structure (Figure S1B). This protocol was previously applied to the design of an immunogenic protein incorporating a viral epitope, but in that case, the incorporated epitope provided all necessary interactions with a target antibody (Correia et al., 2014). Here, the incorporated Bim-BH3 motif provides only a fraction of the interaction surface (~40%), with potential for many additional contacts across an expansive interface.

Each designed protein in the ensemble was docked to the BHRF1 surface via alignment of the incorporated Bim-BH3 motif, and the surrounding interface residues were optimized as described above. The designs were filtered both for stability of the monomer and for interface quality. From thousands of computer-assembled proteins, a small number of designs were selected for further manual modifications, synthetic E. coli codon-optimized genes were constructed, and those proteins that were expressed and soluble in E. coli were tested by yeast surface display for binding to BHRF1 (Table S2; yeast surface display allows rapid measurement of approximate affinities and is a powerful technology for later directed evolution). Two designs with folds based on PDB 3LHP(S) were found to bind BHRF1 with apparent K_D of 58–60 nM (BbpD04 and BbpD07; Figure 1A, Table 1, and Data S1). These designs were “seeded” by a 15 residue fragment of the Bim-BH3 motif of which nine side
chains contacting the BHRF1 surface were kept fixed. Other residues, primarily on the backside of the motif and buried in the protein core, were designed to minimize the calculated potential energy. The equivalent 3LHP(S) fixed backbone graft (design BbpG1.D, Table S1) had numerous steric clashes between the scaffold backbone and BHRF1 surface in the computational model (described later) and failed to bind BHRF1.

In Silico Folding Probability Correlates with Binding Activity
The success rate for designing functional proteins is low, and design calculations are often followed by substantial human intervention to choose and modify the designs prior to experimental validation (Figure S2A). To investigate the factors distinguishing working from nonworking designs and to evaluate the importance of human intervention, we characterized BHRF1 binding to a set of computational designs generated as described for BbpD04 and BbpD07 but without any human modifications. Seventy-four designs were displayed on yeast (Data S1) and sorted with a single round of fluorescence-activated cell sorting (FACS) for surface protein expression and BHRF1 binding. Deep sequencing revealed that five designs (indexes 00 to 04 in Data S1) were highly expressed and enriched after sorting for BHRF1 interaction (Figures 1B and S2A–S2D and Table S3); BHRF1 binding was confirmed on clonal yeast populations (Figure S2E). Standard computational metrics for assessing interface quality or monomer stability did not distinguish the working designs (Figures S2F–S2K). Instead, we found that BHRF1 binding strongly correlated with the extent to which the designed sequences folded to the designed structures in

Figure 1. Computationally Designed Proteins Incorporating Elements of the Bim-BH3 Motif Bind BHRF1
(A) Computational models of individually tested designed proteins (orange) that bind BHRF1 (green). The crystal structure of BHRF1 bound to Bim-BH3 (blue) is shown at left for comparison. BbpG designs are from side-chain grafting, and BbpD designs are de novo assembled proteins. Apparent affinities (mean ± SE, n = 3–6) are from yeast display titrations. See also Figure S1 and Tables S1 and S2. An archive file of designed structures is provided in the Supplemental Information online (Data S1).
(B) Seventy-four computationally designed proteins without human modifications (indexes 01 to 74 in Data S1) were included in a yeast display library. BbpD04 (index 00) was included as a positive control. The library was sorted for cells expressing surface protein (lane 1), for the 2% of cells with highest expression (lane 2), and for cells showing binding signal after incubation with 100 nM (lane 3) or 400 nM BHRF1 (lane 4). The gene frequencies in the sorted population were divided by their frequencies in the naive library to calculate a log₂ enrichment ratio, plotted from −4 (i.e., depleted, red) to +4 (i.e., enriched, green). See also Table S3.
(C) Histogram of the mean rmsd between the ten lowest energy structures found in ab initio structure prediction calculations and the intended designed structure for each of the sets of designs in (B). Designs with computed energy minima near the designed target conformation have a higher probability of binding BHRF1. See also Figure S2.
ab initio structure prediction calculations (Figures 1C and S2L). Rather than a single calculated metric from a static representation of the structure, ab initio structure prediction generates tens of thousands of conformations from stochastic folding simulations. Among the designs that bind BHRF1, the closer the predicted conformations are to the designed structure (i.e., lower rmsd in Figure 1C), the lower their calculated energy and hence the higher the probability of correctly folding. This observation suggests that the primary shortcomings of inactive designs are improper folding and designed state instability, rather than the details of the designed protein-protein interface.

Enhanced BHRF1 Binding Affinity and Specificity through Improved Electrostatic Complementarity

To illuminate BHRF1 biology, the designed protein must not only bind with high affinity but do so specifically. Design BbpD04, a de novo designed protein without sequence homologs identified by BLAST (Altschul et al., 1997), bound BHRF1 with higher affinity (apparent $K_D = 58 \pm 3$ nM) than all human prosurvival Bcl-2 proteins except Mcl-1 (Table 1) and was chosen for further optimization. The computed electric field (Baker et al., 2001) experienced by BbpD04 when bound to BHRF1 is markedly more negative than when bound to Mcl-1 (Figures 2A and 2B). Nine point substitutions were made to eight residues of BbpD04 to specifically increase electrostatic complementarity for BHRF1. Six decreased the $K_D$(BHRF1)/$K_D$(Mcl-1) ratio as predicted (Table S4). The variant BbpD04.1 containing the best two point mutations (E48R and E65R), together with a third compensatory mutation (K31E) to preserve a putative stabilizing salt bridge, bound BHRF1 with tighter affinity (Table 1).

Optimization of Affinity, Specificity, and Stability

Error-prone PCR mutagenesis of BbpD04.1, followed by FACS for BHRF1 binding in the presence of unlabeled human Bcl-2 proteins to favor specificity, identified two mutations at the designed interface (H104R, predicted to enhance electrostatic complementarity, and N62S, predicted to improve specificity based on sequence-fitness landscape mapping described below) and three mutations distal from the interface that might alter protein stability. I21L slightly alters packing in the hydrophobic core, Q79L increases hydrophobic interactions buttressing the second connecting loop, and L84Q forms a stabilizing hydrogen bond to the loop backbone. The substitutions were recombined in a combinatorial library, and FACS followed by analysis of expression in E. coli identified a clone, BbpD04.2 (with four mutations, see Figure 2C), that was monodisperse and monomeric by size exclusion chromatography (SEC) after protein purification from E. coli (Figure S3). To enable site-specific chemical coupling for later characterization, the single internal cysteine of BbpD04.2 was removed by mutagenesis (mutant C103A, called BbpD04.3; Table 1 and Figure S4). To probe the sequence-fitness landscape of the designed protein, site-specific saturation mutagenesis was used to independently diversify every codon of the BbpD04.3 gene to NNK (N is any base, K is G or T), producing a library of (116 positions) × (20 amino acids + stop codon) = 2,436 protein variants. The variants were expressed on yeast, and the library was sorted by a single round of FACS for BHRF1 affinity (Figure 2D) or affinity and specificity (unlabeled human Bcl-2 proteins were included as competitors; Figure 2E). DNA was extracted from the naive and postsorted yeast populations, and the BbpD04.3 coding region was deep sequenced. The ratio of the frequencies of each protein variant in the presorted and postsorted population reports on the effect of each substitution on affinity/specificity fitness.

The comprehensive BbpD04.3 affinity sequence-fitness landscape reveals the critical nature of the incorporated Bim-BH3 motif, with most substitutions of interface residues depleted (Figure 2D). In addition, substitutions to proline, which can break regular helical secondary structure, are depleted across the first, second, and third helical spans of the designed helical bundle fold. Substitutions to aspartate, a short and charged amino acid, are depleted within the hydrophobic core as anticipated.

Table 1. Affinities of Designed Proteins for Bcl-2 Family Members

<table>
<thead>
<tr>
<th>Protein</th>
<th>BHRF1</th>
<th>Bcl-2</th>
<th>Bcl-w</th>
<th>Mcl-1</th>
<th>Bfl-1</th>
<th>Bcl-X</th>
<th>Bcl-B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bim-BH3</td>
<td>$12 \pm 4$</td>
<td>$2.02 \pm 0.08$</td>
<td>$2.1 \pm 0.1$</td>
<td>$0.6 \pm 0.2$</td>
<td>$2.1 \pm 0.3$</td>
<td>$3 \pm 1$</td>
<td>$12.2 \pm 0.1$</td>
</tr>
<tr>
<td>BbpG2.D</td>
<td>$60 \pm 8$</td>
<td>$9 \pm 1$</td>
<td>&gt;100</td>
<td>$1.5 \pm 0.3$</td>
<td>–</td>
<td>$106 \pm 9$</td>
<td>&gt;100</td>
</tr>
<tr>
<td>BbpG3.D</td>
<td>$70 \pm 20$</td>
<td>$20 \pm 2$</td>
<td>$4 \pm 2$</td>
<td>$9 \pm 2$</td>
<td>–</td>
<td>$31 \pm 3$</td>
<td>$79 \pm 8$</td>
</tr>
<tr>
<td>BbpG4.D</td>
<td>$81 \pm 8$</td>
<td>&gt;100</td>
<td>$35 \pm 4$</td>
<td>$20 \pm 3$</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>$80 \pm 4$</td>
</tr>
<tr>
<td>BbpD07</td>
<td>$60 \pm 10$</td>
<td>$76 \pm 7$</td>
<td>–</td>
<td>$3.1 \pm 0.3$</td>
<td>&gt;100</td>
<td>–</td>
<td>&gt;100</td>
</tr>
<tr>
<td>BbpD04</td>
<td>$58 \pm 3$</td>
<td>–</td>
<td>–</td>
<td>$17 \pm 7$</td>
<td>&gt;100</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>BbpD04.1</td>
<td>$8 \pm 4$</td>
<td>$110 \pm 20$</td>
<td>$14 \pm 5$</td>
<td>$30 \pm 10$</td>
<td>&gt;100</td>
<td>$25 \pm 1$</td>
<td>–</td>
</tr>
<tr>
<td>BbpD04.2</td>
<td>$0.6 \pm 0.2$</td>
<td>$33 \pm 4$</td>
<td>$40 \pm 10$</td>
<td>$26 \pm 4$</td>
<td>$70 \pm 20$</td>
<td>$31 \pm 2$</td>
<td>–</td>
</tr>
<tr>
<td>BbpD04.3</td>
<td>$0.54 \pm 0.01$</td>
<td>$20 \pm 2$</td>
<td>$34 \pm 3$</td>
<td>$19 \pm 1$</td>
<td>$32 \pm 6$</td>
<td>$34 \pm 7$</td>
<td>–</td>
</tr>
<tr>
<td>BINDI</td>
<td>$0.9 \pm 0.2$</td>
<td>$45 \pm 7$</td>
<td>$60 \pm 10$</td>
<td>$21.6 \pm 0.8$</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>–</td>
</tr>
</tbody>
</table>

Accurate dissociation constants measured by BLI (nM; mean ± SD, n = 4–6)

<table>
<thead>
<tr>
<th>Protein</th>
<th>BHRF1</th>
<th>Bcl-2</th>
<th>Bcl-w</th>
<th>Mcl-1</th>
<th>Bfl-1</th>
<th>Bcl-X</th>
<th>Bcl-B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bim-BH3</td>
<td>$7 \pm 3$</td>
<td>$0.75 \pm 0.09$</td>
<td>$20 \pm 10$</td>
<td>$0.17 \pm 0.02$</td>
<td>$0.61 \pm 0.04$</td>
<td>$1.56 \pm 0.09$</td>
<td>$7 \pm 2$</td>
</tr>
<tr>
<td>BINDI</td>
<td>$0.22 \pm 0.05$</td>
<td>$2.100 \pm 100$</td>
<td>$870 \pm 40$</td>
<td>$40 \pm 10$</td>
<td>$2,600 \pm 800$</td>
<td>$810 \pm 80$</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>BINDI N62S</td>
<td>$0.16 \pm 0.08$</td>
<td>$30,000 \pm 10,000$</td>
<td>$4,600 \pm 400$</td>
<td>$230 \pm 40$</td>
<td>$4,000 \pm 2,000$</td>
<td>$8,000 \pm 2,000$</td>
<td>$50,000 \pm 10,000$</td>
</tr>
</tbody>
</table>
Figure 2. Affinity Maturation of BbpD04

(A) Computational model of BHRF1 (light green ribbon) bound to design BbpD04 (transparent surface over a gray ribbon). The electrostatic potential from BHRF1 is shown on the BbpD04 surface (red, $-2\ kT/e$ to blue, $+2\ kT/e$; calculated using the Adaptive Poisson-Boltzmann Solver built in ROSETTA). Mutations E48R and E65R (insets) decrease electrostatic repulsion in regions where the field from BHRF1 is negative.

(B) Same as in (A), with Mcl-1 in place of BHRF1. E48 and E65 are now in regions that border positive potential from Mcl-1. The Mcl-1-BbpD04 model was generated by superposition of the BbpD04 binding site to Bim-BH3 bound to Mcl-1 in crystal structure 2PQK, followed by rotamer repacking and side-chain/backbone minimization in ROSETTA. See also Table S4.

(C) The four additional mutations in BbpD04.2 (dark blue sticks) are shown on the computational model of BbpD04.1 (orange) bound to BHRF1 (green). Three mutations are distant from the interface. See also Figures S3 and S4.
The BbpD04.3 affinity-specificity sequence-fitness landscape, in which unlabeled Bcl-2 proteins were included as competitors for BHRF1 binding, is similar (Figure 2E). Notably, several mutations of Asn62, including N62S described in detail later, were found to selectively increase BHRF1 specificity.

Bacterial expression of BbpD04.3 was very low, limiting the quantity and purity that could be purified for biochemical applications. To improve expression, 29 BbpD04.3 point mutants with positive enrichment ratios in either the affinity or affinity-specificity sequence-fitness landscapes were expressed in E. coli and analyzed for increased soluble protein levels (Figure S5A). All nine identified mutations—W3A/P, I13Q, F28L, M33R, F61Y, W49E/Y, and M46E—reduce surface hydrophobicity, and, in addition, W3A and W3P increase the helical propensity of the initiating residue in the starting helix. These substitutions perhaps reduce misfolding or aggregation, thereby reducing clearance of the protein by the quality control machinery. Because the mutations are generally surface exposed at distinct sites on a long helical bundle, we reasoned that they could likely be combined without negative interference (Figure S5B). A BbpD04.3 variant with seven mutations (Figure S5C) had significantly increased bacterial expression and improved specificity (Figure 2G and Table 1). This variant is named BHRF1-Inhibiting Design acting Intracellularly (BINDI). A summary of all mutations introduced in the original design is provided in Figure 2I.

The increased affinity for BHRF1 following in vitro evolution correlates with enhanced protein stability. Both BbpD04.3 and BINDI undergo cooperative unfolding at high concentrations (>3 M) of the chemical denaturant guanidinium hydrochloride measured by circular dichroism (CD) spectroscopy (Figure 2H). However, the original design, BbpD04, has nearly linear loss of CD signal over a wide concentration range of guanidinium hydrochloride (Figure 2H). The absence of a cooperative melting transition is associated with molten globules that lack a rigid core or single native conformation. Although BbpD04, BbpD04.3, and BINDI have high thermostability and retain partly α-helical CD spectra at 95 °C, only evolved BbpD04.3 and BINDI fully renature when the heated proteins are cooled (Figures S5D–S5G). Further, the original BbpD04 design is sensitive to rapid hydrolysis by proteases, which require unfolded substrate backbone to access the enzyme active site, whereas BINDI and BbpD04.3 are resistant (Figure S5H).

BINDI Binds BHRF1 with High Affinity and Specificity

Apparent dissociation constants by yeast surface display are useful approximations but may be underestimated due to avidity effects or ligand rebinding to a dense receptor surface or may be overestimated if binding equilibrium is not reached. The BINDI-BHRF1 interaction was therefore further characterized by alternative methods. BINDI eluted as a higher-molecular-weight complex by SEC when mixed with BHRF1 in solution, whereas BINDI L54E with a knockout mutation in the designed interface did not (Figures 3A and S3). Using bio-layer interferometry (BLI) to measure the kinetic rate constants, BINDI-BHRF1 was found to form a very tight complex (K_D 220 ± 50 pM) with a slow dissociation rate (k_off = [2.8 ± 0.9] × 10^{-5} s^{-1}) (Figures 3B and 3D). BINDI has high specificity for BHRF1; the dissociation constants for human Bcl-2 family members are much weaker. BINDI bound human Mcl-1 with K_D 40 ± 10 nM (180-fold increase compared to BHRF1), Bcl-2 with K_D 2.1 ± 0.1 μM (10,000-fold increase), Bcl-w with K_D 870 ± 40 nM (4,000-fold increase), Bfl-1 with K_D 2.6 ± 0.8 μM (12,000-fold increase), Bcl-B with K_D > 10 μM (>45,000-fold increase), and Bcl-X₀ with K_D 810 ± 80 nM (4,000-fold increase). The N62S variant of BINDI was found to have even higher specificity for BHRF1 versus Mcl-1, the closest competitor (Figure 3E). Compared to the measured affinities of Bcl-2 proteins for Bm-BH3 (Figure 3C) and to other published values (Caria et al., 2012; Dutta et al., 2010, 2013; Gemperli et al., 2005; Kvantakul et al., 2010; Lessene et al., 2013; Tse et al., 2008), the affinity and specificity of BINDI for BHRF1 are considerably greater than any previously described BHRF1 ligand and are similar to or exceed that of any other protein, peptide, or drug designed to specifically bind a Bcl-2 family protein.

The Crystal Structure of BINDI-BHRF1

The crystal structure of the BINDI-BHRF1 complex was determined at 2.05 Å resolution (Figure 4A and Table S5) and was found to closely match the design model. The asymmetric unit contains two nearly identical copies of BINDI-bound BHRF1; the analysis presented here corresponds to one copy of the complex (Figures S6A and S6B). The backbones of the crystal structure and the original BbpD04+BHRF1 model align with a Cz-Cz RMSD of 1.06 Å (Figure 4B). The designed core and interface regions were modeled accurately, whereas connecting loops at the ends of the helical bundle deviate slightly from the computational prediction (Figure 4C). Excluding flexible termini, only two regions differ substantially from the model; BHRF1 loop 74-78 and BHRF1 loop 92-97 are located further away from the interface in the crystal structure by 3 to 5 Å (Figures 4C, S6C, and S6D). Our computational modeling assumed that the target...
BHRF1 backbone was rigid, and therefore, changes to the target structure could not be anticipated. These regions have been found to be flexible in BHRF1 and other Bcl-2 family members to accommodate the binding of different BH3 motif ligands (Fire et al., 2010; Kvansakul et al., 2010; Lee et al., 2009).

BINDI incorporates the Bim-BH3 motif within a de novo designed fold guided by the topology of PDB 3LHP chain S. As noted earlier, the direct graft of Bim-BH3 interaction residues to the equivalent site within the 3LHP(S) scaffold (design BbpG1) failed to bind BHRF1, even after extensive design of the surrounding interaction surface (design BbpG1.D; Table S1). Although 3LHP(S) is structurally similar to BINDI, it is nonetheless a poor steric fit for the BHRF1-binding groove in this design protocol. Aligning the graft site within 3LHP(S) to the Bim-BH3 motif of BINDI in the BINDI-BHRF1 crystal structure shows that the C-terminal helix of the grafted design comes too close to the BHRF1 surface such that side chains would clash (Figure 4D). An alignment of the crystal structure, design model, and guide scaffold over the Bim-BH3 incorporation site shows that the crystal structure is closer to the design model than to the guide scaffold (Figure 4E). The rmsd between the crystal and design models is 1.37 Å and is 1.86 Å between the crystal and guide scaffold. Thus, the design process succeeded in identifying a sequence that folds more closely to the designed model than to the structure of the initial guide scaffold.

Compared to the native Bim-BH3 interaction, BINDI contacts an additional 404 Å² on the surface of BHRF1 (Figures 4F–4K). Residues from the Bim fragment that seeded design account for just 587 Å² of the BINDI surface buried in the complex, whereas designed residues account for 839 Å² (Figure 4H). Only two residues at the periphery of the incorporated Bim-BH3 motif changed during affinity maturation (the conservative W49Y and F61Y substitutions), whereas all residues in the core of the motif remained unchanged (Figures S6E–S6G). Introducing these two mutations into a Bim-BH3 peptide, or mutating the Bim-BH3 peptide at all five positions within the BH3 region that distinguish BbpD04 from specific BINDI, failed to achieve the high affinity and specificity of BINDI (Figures S6H and S6I). Likewise, excised peptides from BbpD04 and BINDI that could be considered equivalent to a 26 residue BH3 motif, although partially specific, again lack the affinity and specificity of BINDI (Figures S6H and S6I). The extraordinary specificity of BINDI is therefore accomplished through interactions across an expansive interface, extending well beyond the central Bim-BH3 residues used to seed design.

**BINDI Triggers Apoptosis Preferentially in EBV-Infected Cells**

We tested whether inhibition of BHRF1 via steric occlusion of the BH3-binding groove with BINDI could induce mitochondrial cytochrome c release in the EBV-positive BL cell line Ramos-AW. Ramos-AW expresses BHRF1 at very low levels (Leao et al., 2007) and therefore presents a challenging biological target that likely expresses much higher levels of off-target endogenous Bcl-2 family proteins. BINDI was applied to mitochondria isolated from both Ramos-AW and the EBV-negative parental line Ramos (Andersson and Lindahl, 1976). BINDI elicited greater cytochrome c release from Ramos-AW mitochondria (Figure 5A), indicating that an EBV-associated factor wraps around the BH3 region.
is likely a BNDI target. Strikingly, the nonspecific Bim-BH3 peptide had opposite behavior; mitochondria from EBV-negative Ramos cells were more sensitive to Bim-BH3 treatment than those from EBV-positive Ramos-AW cells. Indeed, EBV-positive cell lines are widely reported as more resistant to nonselective apoptotic stimuli (Ishii et al., 1995; Kvansakul et al., 2010; Leao et al., 2007), making the enhanced activity of BNDI against Ramos-AW cells all the more significant.

Although weaker than the picomolar affinity of BNDI for BHRF1, the moderate affinity for Mcl-1 is likely the reason BNDI still triggers apoptosis in the EBV-negative Ramos cell line. It is possible that the enhanced toxicity of BNDI toward...
Ramos-AW reflects increased Mcl-1-dependency in this line, rather than expression of EBV BHRF1. To rule out this possibility, we tested variant BINDI N62S with even greater specificity. Asn62 of BINDI hydrogen bonds to the N terminus of BHRF1 helix α6, and serine at this position is predicted to similarly interact at the interface (Figure S7B). BINDI N62S still binds BHRF1 with tight affinity (K_D 160 ± 80 pM) but with better specificity (Table 1 and Figure 3E); in particular, the affinity for Mcl-1 is diminished 6-fold (K_D 230 ± 40 nM). BINDI N62S has even greater discrimination between Ramos and Ramos-AW cells (Figure 5B). The enhanced activity of BINDI to initiate cytochrome c release preferentially in EBV-positive cells is therefore almost certainly due to BHRF1 inhibition.

Expression profiling of EBV-positive BLs has revealed distinct subgroups (Kelly et al., 2013; Watanabe et al., 2010), and BHRF1 may not be important for cell survival in all cases. Including Ramos and Ramos-AW, mitochondria were isolated from five EBV-positive and three EBV-negative B cell lines. Bim-BH3 peptide triggered cytochrome c release, whereas the inactive guide scaffold 3LHP(S) had no effect (Figure S7C). Incubation with BINDI N62S induced high cytochrome c release in three EBV-positive lines (Figures 5B and 5C): BL lines Ramos-AW and Daudi and B-prolymphocytic leukemia JVM-13. Two of the EBV-positive lines had low levels of cytochrome c release similar to EBV-negative cells, despite transcribing the BHRF1 gene (Figure S7C): BL line Raji and mantle cell lymphoma line JVM-2. Hence, only some EBV-positive cancer lines appear to be dependent on BHRF1 for survival.

BINDI was genetically fused with a C-terminal antennapedia peptide for nonspecific cellular uptake and intracellular delivery in vitro. BINDI-antennapedia applied to the growth medium at 4 μM selectively killed 40% of EBV-positive Ramos-AW cells with no measurable death of EBV-negative Ramos cells (Figure 6A). BINDI-antennapedia was conjugated via a terminal cysteine to a diblock copolymer carrier, Pol300, comprising a hydrophilic first block and a pH-responsive endosomolytic second block (Convertine et al., 2010; Duvall et al., 2010; Manganiello et al., 2012). A lower 2 μM dose of BINDI-antennapedia induced 60% cell death preferentially in Ramos-AW cells when conjugated to the Pol300 polymeric carrier for enhanced cytosolic delivery (Figure 5D). Our data suggest that inhibition of BHRF1 may effectively kill EBV-positive BL.

**Figure 5. BINDI Triggers Apoptosis in EBV-Positive B Cell Lines**

(A) Cytochrome c release from mitochondria harvested from Ramos (EBV negative, gray) or Ramos-AW cells (EBV positive, crimson) treated with Bim-BH3 peptide (broken line) or BINDI (solid line). Mean ± SD, n = 4, for (A)–(C). See also Figure S7.

(B) Cytochrome c release from Ramos and Ramos-AW mitochondria treated with 10 μM BINDI or BINDI N62S.

(C) Mitochondria were harvested from EBV-negative and -positive lines, and cytochrome c release was measured after treatment with 10 μM BINDI N62S.

(D) Cells were incubated with sublethal doses (2 μM) of antennapedia peptide-fused BINDI or 3LHP(S). Diblock copolymer Pol300 was conjugated to the proteins for enhanced endosomal escape. Cell viability (mean ± SD, n = 3) was measured after 24 hr.

**Figure 6. In Vivo Delivery of BINDI and 3LHP(S)**

(A) Cytochrome c release from Ramos mitochondria treated with 10 μM BINDI or BINDI N62S.

(B) Cytochrome c release from Ramos-AW mitochondria treated with 10 μM BINDI or BINDI N62S.

(C) Cytochrome c release from Ramos mitochondria treated with 10 μM BINDI or BINDI N62S.

(D) Cells were incubated with sublethal doses (2 μM) of antennapedia peptide-fused BINDI or 3LHP(S). Diblock copolymer Pol300 was conjugated to the proteins for enhanced endosomal escape. Cell viability (mean ± SD, n = 3) was measured after 24 hr.
and protein drug release in the reducing environment of the cytosol.

Subcutaneous Ramos-AW xenograft tumors were established in nude BALB/c mice. The mice were treated intravenously on days 0, 3, and 6 with antibody micelles coupled to the inactive scaffold 3LHP(S) or to BINDI. Thirty minutes prior to each treatment, cyclophosphamide (CTX) and bortezomib (BTZ) were injected intraperitoneally at subtherapeutic doses to prime cells for apoptosis ([O’Connor et al., 2006]). The treatments were nontoxic with no substantial change in mouse body weight ([Figure S7E]).

The intracellular delivery of BINDI to the B cell lymphoma xenograft slowed tumor progression and prolonged survival. Tumors grew rapidly in the untreated/PBS and chemo-only control groups ([Figures 6B and 6C]), with mean tumor sizes of 1,080 ± 500 mm³ and 680 ± 410 mm³, respectively, at day 11 when the first mice were euthanized due to excessive tumor burden. Both scaffold 3LHP(S) and BINDI treatment groups had reduced tumor sizes due to the therapeutic effects of αCD19 coupled to the micelle carrier, but BINDI substantially slowed tumor growth compared to the scaffold control, especially during the treatment cycle (140 ± 60 mm³ versus 330 ± 140 mm³ at day 11, unpaired t test p = 0.003, [Figures 6D and 6E]). Life span was extended in the BINDI-treated mice compared to the scaffold treatment (log-rank test p = 0.006), with median survival of 15 days for PBS treatment, 16 days for chemo only, and 21 days for 3LHP(S) treatment, extending to 24 days following BINDI treatment ([Figure 6F]). Future work is needed to determine the fraction of proteins delivered with this new delivery carrier that are internalized and directly engage intracellular targets.

Nonetheless, our data demonstrate that a de novo computationally designed protein can reduce tumor growth in a preclinical model.

DISCUSSION

By breaking free of the conformational constraints imposed by repurposing pre-existing scaffolds and instead building a new protein with structure tailored for the target surface, a remarkably tight and specific binder of the EBV apoptosis regulator BHRF1 was designed. The elevated toxicity of the engineered BINDI protein toward EBV-positive cancer lines supports the hypothesis that BHRF1 is necessary for survival in at least some EBV-associated cancers.

BINDI has a structure and amino acid sequence found after computationally filtering thousands of potential designed conformations for optimum interactions with BHRF1. The crystal structure is very close to the BINDI computational model, with the orientations of helices differing from the guide scaffold in ways critical for activity. The ability to custom tailor the backbone...
conformation to the challenge at hand was critical to our success in achieving very high affinity and specificity.

Protein structure and function are closely coupled, and our results demonstrate the importance of designing for stability in addition to optimizing the binding interface. Designs with BHFR1 binding activity had energy minima near the intended target structure in ab initio structure calculations and directed evolution of BbpD04 to enhance affinity introduced mutations far from the interface that increased protein stability. Direct in silico screening for a deep energy minimum around the desired conformation could considerably increase the success rate of protein design efforts.

Finally, we demonstrate that BINDI can slow progression of EBV-positive B cell lymphoma and prolong survival in a human xenograft mouse model. The suppression of tumor growth during treatment with BINDI provides proof-of-principle results that a designer protein toxin can be antibody targeted and effective in vivo. Further optimization of dosing, targeting, and the carrier may all increase therapeutic efficacy, and incorporation of catalytic activity in the designed protein, for example site-specific proteolysis, would boost potency. Designer toxins with high potency and specificity could provide the basis for a next generation of antibody-drug conjugates for the treatment of cancer.

**EXPERIMENTAL PROCEDURES**

**Protein Design and Purification**

Proteins were designed using the ROSETTA software suite, and designed protein genes were synthesized by oligo assembly or by commercial suppliers. Designed proteins (cloned into pET29b [Novagen]) were purified with C-terminal 6His-tags from *E. coli* BL21(DE3) by NINTA-affinity chromatography (Qiagen) and SEC (GE Healthcare). Target Bcl-2 proteins had C-terminal avi-6His tags and were similarly purified from *E. coli*, followed by enzymatic biotinylation using BirA (AviDyne). Biotinylated proteins were further purified by additional rounds of NINTA-affinity chromatography and SEC. All purified proteins were concentrated with ultrafiltration centrifugal devices (Sartorius), snap frozen in liquid nitrogen and stored at −80°C.

**Yeast Surface Display**

Design optimization was by yeast surface display. Designed protein genes were cloned into plasmid pETCON (Fleishman et al., 2011) and expressed as fusions with N-terminal Aga2p for surface attachment and a C-terminal myc-tag in the EBY100 strain. Surface expression was detected with anti-myc-FITC (Immunology Consultants Laboratory), whereas binding to myc-tag in the EBY100 strain. Surface expression was detected with phycoerythrin-streptavidin (Invitro). Design optimization was by yeast surface display. Designed protein genes were synthesized with site-specific saturation mutagenesis library (Procko et al., 2013), or by error-prone PCR with an average error rate of 1.3 aa substitutions per clone using GeneMorph II Random Mutagenesis (Agilent Technologies), snap frozen in liquid nitrogen and stored at −80°C.

**Xenograft Disease Model**

BALB/c nu/nu mice (6 to 8 weeks old) were housed under protocols approved by the FHCRC Institutional Animal Care and Use Committee. Ramos-AW cells (10^5 cells/200 μl) were injected in the right flank (day 0), and tumors grew for 6 days to a volume of 50 mm^3^ . Mice with similar-sized tumors were sorted randomly into treatment groups (n = 8 to 10). On days 0, 3, and 6, mice were injected intraperitoneally with CTX (35 mg/kg) and BTZ (0.5 mg/kg). After 0.5 hr, mice were injected with tail vein with conjugates at a dose of 15 mg/kg (sCD19; clone CAT-1E10 made in the monoclonal production facility at FHCRC), 300 mg/kg (Pol950), and 105 mg/kg (BINDI or 3LHP). Body weight was monitored for toxicity, and tumor sizes were measured while blinded to treatment groups. Mice were euthanized when tumors reached a volume of 1,250 mm^3^.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, seven figures, one data file, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2014.04.034.

**AUTHOR CONTRIBUTIONS**

E.P., computationally designed proteins with assistance from Y.S. and B.E.C.; E.P., optimized, purified, and characterized proteins with assistance from Y.C.; G.Y.B. and E.P. measured mitochondrial cytochrome c release with assistance from D.M.; G.Y.B. developed the micelle carrier with assistance from A.J.C. and performed animal studies with assistance from S.F. and G.B.; B.W.S. crystallized BINDI-bound BHRF1 and determined the structure; E.P. drafted the manuscript with edits and input from all authors; and W.R.S., D.M.H., O.W.P., B.L.S., P.S.S., and D.B. supervised research.

**ACKNOWLEDGMENTS**

This work was supported by the National Institute of General Medical Studies of the National Institutes of Health (NIH) under award numbers P41GM103533 and R01GM49857; NIH grants R21EB014572, R01CA076287, and R01CA154897; the Washington State Life Sciences Discovery Fund grant 2496490 to the Center for Intracellular Delivery of Biologics; the Defense Threat Reduction Agency; and a grant by the David and Patricia Giuliani Family Foundation. Computational resources were provided by BOING and supported by the National Science Foundation through awards SCI-0221529,


